ADC Therapeutics (NYSE:ADCT – Get Free Report) announced its earnings results on Monday. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.15, reports. The company had revenue of $21.72 million for the quarter, compared to the consensus estimate of $18.69 million. During the same period in the previous year, the firm posted ($0.30) EPS.
ADC Therapeutics Stock Performance
Shares of ADC Therapeutics stock opened at $1.57 on Monday. The firm has a 50-day moving average of $1.36 and a 200-day moving average of $2.43. The stock has a market cap of $201.08 million, a PE ratio of -2.39 and a beta of 1.82. ADC Therapeutics has a 52-week low of $0.78 and a 52-week high of $4.98.
Analysts Set New Price Targets
Several research analysts have weighed in on ADCT shares. Wall Street Zen raised shares of ADC Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of ADC Therapeutics in a research report on Thursday, October 15th. Finally, Guggenheim reduced their price objective on ADC Therapeutics to $5.00 and set a “buy” rating for the company in a report on Monday, August 17th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $5.00.
View Our Latest Research Report on ADCT
About ADC Therapeutics
ADC Therapeutics SA (NYSE: ADCT) is a biotechnology company focused on developing and commercializing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC platform is designed to combine monoclonal antibodies that target specific tumor-associated antigens with potent cytotoxic payloads, with the goal of selectively delivering treatment to cancer cells while limiting exposure to healthy tissue.
The company’s lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed against the CD19 antigen.
Featured Stories
- Five stocks we like better than ADC Therapeutics
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
